Generation Lab’s Secret Youth Shot Has a Copycat Problem

Generation Lab is offering a weekly shot of two unnamed generic drugs, called 1 Generation, to a private celebrity waitlist before it has published human results. The Burlingame, California, company says the mix blocks aging signals in the blood and wakes the body’s own repair systems.

It does not own those two drugs. That gap, more than the waitlist, is the business.

A Celebrity Waitlist for Two Unnamed Generics

Alina Rui Su, the 26-year-old chief executive, told interviewers there is already a long line of famous names. She called 1 Generation the first longevity drug that is in the human body and working. The company fact sheet goes further. It says the shot “blocks the systemic spread of aging in the bloodstream, reawakens the body’s own repair mechanism and restores health and youth to multiple tissues.”

There’s a long wait list including a lot of celebrities, well-known people, people who you have heard of. So we’re super excited to, like, create this drug and letting you know that this first longevity therapeutic in the human body is here and it’s actually working.

Alina Rui Su, CEO, Generation Lab

The offer went out as a private cohort under a doctor’s eye, pitched to people whose “judgment on the science” the firm said it trusted. Irina Conboy, the scientific founder, has been taking the combination for about two months and says she feels better and more energetic. So have Su and Michael Conboy, Irina’s husband and longtime lab partner. A company spreadsheet on that handful of insiders listed sharper vision in a 64-year-old woman, longer landscaping sessions for a 59-year-old man, longer badminton games, a stronger hand grip, erections “better than with Viagra,” and more bowel movements.

That is not a controlled trial. Su says Generation Lab will run a larger study in a hundred or more people, paid for by the company and free to volunteers. People can still pay a doctor for the shot outside that study. The two drug names stay confidential, Su said, to keep imitators off the formula.

That secrecy is already the thing people argue about. The first question from readers who follow aging science is not whether Conboy’s mouse work is interesting. It is when the names leak, and whether two generics anyone can already write will stay a company product for long.

Irina Conboy Spent 20 Years Proving Old Blood Wins

The reason the pitch landed at all is Conboy’s record, not the spreadsheet. At the University of California, Berkeley, she spent two decades on a strange, productive method: joining the blood of old and young animals, then asking which way the aging signals run.

THE PATH FROM JOINED MICE TO A WEEKLY SHOT

1. 2005: Conboy surgically joins two-month-old mice to very old mice and finds the old animals heal from injury far better, a result that launches a hunt for “young blood” factors.
2. 2015: Alkahest, built on Stanford young-plasma work, sells 45 percent of itself to Grifols for $37.5 million, with another $12.5 million pledged, as the field races toward Alzheimer’s and other diseases of age.
3. 2019: The FDA warns that plasma from young donors has “no proven clinical benefit” against aging, after Ambrosia sold a liter for $8,000.
4. 2020: Conboy stops adding young blood and instead pulls plasma from old animals, replacing it with albumin and salt water. Diluting the old factors works even better than sharing a young partner’s blood.
5. End of 2025: Conboy leaves Berkeley and joins Generation Lab full time. The company is already selling an aging blood test and still wants a drug that copies plasma dilution without the apheresis machine.
6. August 2026: Generation Lab offers 1 Generation to a private cohort and, on August 28, hosts an invite-only event with Harvard geneticist George Church.

Conboy’s later work flipped the slogan that made the field famous. Young blood helps an old mouse. Old blood, even in a single plasma swap, hits a young mouse harder. “Old blood dominates,” she says. If the harmful load in aged plasma is the problem, then deleting it, rather than hunting a magic youthful protein, is the practical move.

Longevity clinics understood that faster than drug regulators did. After Conboy’s dilution papers, some began selling therapeutic plasma exchange as a wellness visit, with plasma-exchange visits priced near $10,000. Jeffrey Gladden, a Texas longevity doctor who will take part in Generation Lab’s larger study, has said he flew to California to meet Conboy and to have the procedure himself after reading those papers.

A weekly shot that copies the reset, without a two-hour apheresis session, is the product every one of those clinics would rather sell. That is the commercial logic. It is also why keeping the two names quiet matters more to Generation Lab than it would to a company that actually owned a new molecule.

Male Mice Lived 73 Percent Longer From That Point

Generation Lab still will not confirm what is in 1 Generation. Conboy’s own lab has, for years, published a two-drug stand-in for plasma dilution: oxytocin, a peptide that falls with age, plus a low dose of an Alk5 inhibitor that turns down TGF-beta, a repair-and-fibrosis pathway that rises with age. In talks she has described that mix as the attempt to turn plasma dilution into a shot. Company representatives have told people asking about her patents that 1 Generation is not that pair. The papers are public either way, which is the leak path the waitlist has already created.

The newest mouse study, posted in August 2025 in Aging, treated frail 25-month-old mice, about 75 in human years, with oxytocin plus the Alk5 blocker. Males that got the mix lived 73 percent longer from the start of treatment and showed a 14 percent rise in overall median lifespan, with better endurance, short-term memory, and physical performance. Females did not get a lifespan gain. After a week, both sexes showed a more youthful pattern of blood proteins. After four months, only the males still responded.

OT PLUS A5I IN CONBOY’S 2025 MOUSE STUDY

The female result is the detail a celebrity clinic is least likely to put on a waitlist email. Conboy’s paper is blunt about it. The benefits “manifested only in the male and not in the female mice,” even though a short course helped fertility in middle-aged females. Generation Lab’s own insider notes still flag a 64-year-old woman’s vision. That is a lot of weight to hang on a handful of people, in both sexes, before anyone has stratified human data.

Matt Cook, the Bay Area physician who first agreed to prescribe the company’s combination, was not expecting much. He said his confidence “was going to work was a zero,” because the pair is “two safe, generic drugs that are not even longevity drugs.” Then he took it himself.

The Company Does Not Own the Molecules

Su’s reason for hiding the names is the same reason the moat is thin. Generation Lab did not invent two new compounds. It wants a new use for two old ones. The path for that is a 505(b)(2) application, which lets a firm lean on existing safety files and add fresh clinical work for a new combination or indication. If those new human studies are essential to approval, FDA rules can grant three years of new clinical investigation exclusivity. That clock starts at approval, not at a launch party, and it is shorter than the five years given to a true new chemical entity.

Three years is also narrower than it sounds. It can block a copycat from using the company’s own trial to get a matching combo product approved. It does not stop a doctor from writing the two generics off-label tomorrow, which is already how Cook and a few insiders are taking the shot. It does not stop a compounding pharmacy from filling a similar pair if a physician asks. And it does not stop anyone from reading Conboy’s papers and testing the mix her lab has already described, even if 1 Generation is a different pair.

That is the bind. To earn the three-year window, Generation Lab has to run a real study and put names, doses, and outcomes in an application. To keep a head start before that filing, it has to stay quiet. Every influencer dinner and every clinic partner makes the second job harder. Cook has already said his office is getting calls from high-end doctors, venture capitalists, and biohackers. “People are clamoring for it,” he said. “It’s high-level influencer-type people.”

Last Friday’s private event put Church on a stage with researchers from Anthropic. Church sits on Generation Lab’s advisory board that includes George Church and Aubrey de Grey, and he has said he was also offered the combination. A room like that is useful for fundraising. It is a poor place to hide two drugs that any competent pharmacist could identify from a vial.

The $8,000 Liter and the Companies That Followed

Young-blood medicine has a commercial record, and it is not kind to slogans. Jesse Karmazin’s Ambrosia sold plasma from donors as young as 16 and charged $8,000 for a liter, or $12,000 for two, with clinics in several U.S. cities. In 2019 the FDA told consumers there was no proven benefit for aging or its diseases. Ambrosia shut that product, then resurfaced under another name selling plasma that was no longer billed as strictly young.

Alkahest tried the more careful version: fractionate plasma, run trials in Alzheimer’s and macular degeneration, and partner with a blood-products giant. Grifols’ 2015 check did not produce a marketed rejuvenation drug. Elevian, the Harvard-linked GDF11 company, raised $15 million in November 2020 and a $40 million Series A in September 2021. By 2025 its lead idea was still recombinant GDF11 as a stroke drug in animals, with manufacturing work for an IND, not a product on a clinic menu.

WHAT THE LAST YOUNG-BLOOD WAVE ACTUALLY SOLD

Conboy’s dilution papers were supposed to be the exit from that mess: stop worshipping young donors, remove the old factors, and look for a drug that does the same job. 1 Generation is that exit if the two unnamed generics actually copy the reset in people. It is a sequel to Ambrosia if the evidence stays a celebrity waitlist, a friendly physician network, and a spreadsheet of landscaping hours.

Why Clinic Doctors Can Prescribe Before the Data Exists

Because the ingredients are already approved for other uses, a licensed physician can write them off-label without waiting for Generation Lab’s hundred-person study. That is how Conboy, Su, and Cook have been taking the combination. It is also how the company can seed demand while it still claims it is being careful. Cook runs BioReset Medical, a clinic group that sells other unproven longevity procedures, including stem-cell injections. In 2021 he recommended COVID treatments the FDA called fraudulent, among them inhaling amniotic fluid through a nebulizer. He is now slated to help lead the larger 1 Generation study, alongside other longevity doctors who work outside standard academic trials.

And I have to tell you, it was the most surprising thing that ever happened to me.

Matt Cook, founder, BioReset Medical

Cook said weekly injections brought a stretch of mental clarity that lasted a day, then several days. Other people, he said, reported a sense of well-being and old aches that faded. The pattern, he added, “doesn’t really match what either of the drugs do.” He also said he still does not understand the mechanism and has more questions than answers. Gladden put the same split in fewer words: “I am skeptical and optimistic at the same time.”

WHAT WE KNOW

• The format: 1 Generation is an injectable mix of two existing drugs, taken weekly, that Generation Lab does not own.
• The study plan: A company-sponsored trial in a hundred or more people will be free to volunteers; doctors can still charge for the shot outside it.
• The mouse record: Conboy’s published OT+A5i mix extended frail male mouse lifespan from the treatment date and did not do so in females.

WHAT IS UNCONFIRMED

• The two names: Generation Lab has not identified the drugs in 1 Generation and has said the shot is not the pair in Conboy’s patents.
• Human benefit: Insider notes and Cook’s clarity reports are not blinded, placebo-controlled evidence of age reversal.
• Sex and dose: There is no public human plan that separates men and women the way the 2025 mouse paper did.

Off-label access is the feature that makes a generic combo faster than Elevian’s protein. It is also the feature that makes a three-year exclusivity prize hard to collect. If the mix works, clinics will not wait for an NDA. If it does not, the waitlist will still have been a marketing campaign built on Conboy’s name.

Generation Lab Already Sells Age Tests to 750-Plus Clinics

The shot sits on top of a diagnostics business that is already in doctors’ offices. In October 2025 the company closed an Accel-led $11 million seed round that brought total funding to $15 million, with Samsung Next and funds tied to Steve Aoki, Giannis Antetokounmpo, and Simu Liu also in the round. Accel partner Kerry Wang wrote that the firm was leading the seed and backing the founding trio of Su, Conboy, and Michael Suswal, a co-founder of Standard AI.

In June 2026 Generation Lab launched SystemAge 2.1, a biological-age test it said reads 460-plus biomarkers across 21 organ systems from a needle-free blood draw, with 99 percent accuracy across 1,605 test cases. Su said at the time that the product was in 750-plus clinics in 18 countries. The same network that sells the test is the network that can draw a baseline, inject 1 Generation, and sell a follow-up age score. That loop does not require FDA approval of a new longevity indication. It requires a physician willing to write two generics and a patient willing to pay.

Conboy has said 1 Generation lets human cells “remain young even when they are in the presence of old people’s blood serum,” based on a microfluidic screen she helped build. That is a lab claim about cells in old serum, not a clinical claim about people living longer. The larger study is supposed to close that gap. Until it does, the product in circulation is still a secret pair, a celebrity list, and a set of clinics that learned from Conboy’s papers how to sell the blood reset at luxury prices.

The two drugs still have no public names. The hundred-person study still has no results. Cook’s phone is already ringing.

Disclaimer: This article is news reporting and analysis of a commercial longevity pitch and related published research. It is informational only and is not medical advice, a treatment recommendation, or an assessment of whether any reader should take 1 Generation, oxytocin, an Alk5 inhibitor, plasma exchange, or any other intervention. Anyone considering off-label drugs, clinic infusions, or trial enrollment should speak with a licensed physician who can review their history, medications, and lab work before they act. Figures, clinic counts, trial plans, and product claims reflect company statements and papers as of September 2, 2026, and may change as studies are registered, results appear, or regulators act.